Abivax shares jump after strong trial results on drug obefazimod

Abivax SA

06/10/2025 09:50

** Shares in Abivax ABVX.PA rise more than 4% to their highest price in three weeks, after the French biopharmaceutical company announced positive results from a Phase 3 trial of its obefazimod drug in treatment of ulcerative colitis

** Brokerage Van Lanschot Kempen reiterates its "buy" rating on the stock and more than triples its PT to 65 euros, citing a "dream scenario" for obefazimod

** The data demonstrated a "stellar" 16.4% placebo-adjusted remission rate, comfortably surpassing earlier Phase 2b results, the broker says

** Following the trial results, Kempen doubles its peak sales estimate for the drug to 2.0 billion euros ($2.3 billion) and raises its probability of success for the indication to 75% from 60%

** It adds the strong induction data significantly lowers the risk connected to the upcoming Phase 3 maintenance study results, expected in the Q2 of 2026

** All seven analysts included in LSEG data rate the stock "strong buy" or "buy"

($1 = 0.8566 euros)

(Reporting by Mateusz Rabiega)

((Mateusz.rabiega@thomsonreuters.com))